A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 2051
- Registration Number
- NCT00679627
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2018-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 104
- Registration Number
- NCT00574288
An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 57
- Registration Number
- NCT00544440
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2013-06-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 291
- Registration Number
- NCT00488774
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 400
- Registration Number
- NCT00488319
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2016-04-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1228
- Registration Number
- NCT00488631
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-18
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1065
- Registration Number
- NCT00487539
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 66
- Registration Number
- NCT00473746
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 307
- Registration Number
- NCT00401843
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2018-03-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 2098
- Registration Number
- NCT00338286
© Copyright 2024. All Rights Reserved by MedPath